FDA advisers backed wider compounding access for several peptide drugs
FDA advisers voted to recommend allowing compounding pharmacies to use several peptide substances, despite agency scientists' safety and evidence concerns. The FDA still must decide whether to accept the nonbinding recommendations. (sources: thehill, abcnews, reuters, nytimes)
The FDA advisory committee voted to add peptides, including BPC-157, to the list of substances that compounding pharmacies can use. This decision follows concerns from FDA scientists regarding the lack of demonstrated benefits.
- The FDA committee on compounded drugs voted in favor of adding peptides to the compounding list.
- BPC-157 is among the peptides approved for compounding.
- Agency scientists expressed concerns about the lack of demonstrated benefits for these peptides.
Why it matters
The decision may impact the availability and regulation of peptide treatments in the U.S.
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on Compounded drugs and wellness products
See the current decision, choose your position, and send a message through the issue page.
Take action on Compounded drugs and wellness productsSources used · 4 sources